227 related articles for article (PubMed ID: 37310732)
21. An Atypical ABC Transporter Is Involved in Antifungal Resistance and Host Interactions in the Pathogenic Fungus Cryptococcus neoformans.
Winski CJ; Qian Y; Mobashery S; Santiago-Tirado FH
mBio; 2022 Aug; 13(4):e0153922. PubMed ID: 35726920
[TBL] [Abstract][Full Text] [Related]
22. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
23. Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole.
Kano R; Okubo M; Hasegawa A; Kamata H
Med Mycol; 2017 Nov; 55(8):877-882. PubMed ID: 28927230
[TBL] [Abstract][Full Text] [Related]
24. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
25. Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B.
Carlson T; Lupinacci E; Moseley K; Chandrasekaran S
FEMS Microbiol Lett; 2021 May; 368(7):. PubMed ID: 33877319
[TBL] [Abstract][Full Text] [Related]
26. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
27. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.
Paul S; Doering TL; Moye-Rowley WS
Fungal Genet Biol; 2015 Jan; 74():1-9. PubMed ID: 25445311
[TBL] [Abstract][Full Text] [Related]
28. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
[TBL] [Abstract][Full Text] [Related]
29. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
30. Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in
Gutierrez-Gongora D; Woods M; Prosser RS; Geddes-McAlister J
Microbiol Spectr; 2024 Mar; 12(3):e0284123. PubMed ID: 38329361
[TBL] [Abstract][Full Text] [Related]
31. Host Carbon Dioxide Concentration Is an Independent Stress for Cryptococcus neoformans That Affects Virulence and Antifungal Susceptibility.
Krysan DJ; Zhai B; Beattie SR; Misel KM; Wellington M; Lin X
mBio; 2019 Jul; 10(4):. PubMed ID: 31266878
[TBL] [Abstract][Full Text] [Related]
32. Genotypic diversity and antifungal susceptibility of environmental isolates of Cryptococcus neoformans from the Yangtze River Delta region of East China.
Chen M; Wang Y; Li Y; Hong N; Zhu X; Pan W; Liao W; Xu J; Du J; Chen J
Med Mycol; 2021 Jul; 59(7):653-663. PubMed ID: 33269400
[TBL] [Abstract][Full Text] [Related]
33. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
Gast CE; Basso LR; Bruzual I; Wong B
Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
[TBL] [Abstract][Full Text] [Related]
34. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
35. ATI-2307 Exhibits Equivalent Antifungal Activity in
Gerlach ES; Altamirano S; Yoder JM; Luggya TS; Akampurira A; Meya DB; Boulware DR; Rhein J; Nielsen K
Front Cell Infect Microbiol; 2021; 11():695240. PubMed ID: 34249782
[TBL] [Abstract][Full Text] [Related]
36. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
Chong HS; Dagg R; Malik R; Chen S; Carter D
J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
[TBL] [Abstract][Full Text] [Related]
38. Antifungal Susceptibility of Clinical Isolates and Artificially Produced Multi-azole-resistant Strains of Cryptococcus neoformans (formerly: Cryptococcus grubii) to Ravuconazole.
Kano R; Sugita T; Kamata H
Med Mycol J; 2020; 61(1):11-13. PubMed ID: 32115444
[TBL] [Abstract][Full Text] [Related]
39. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
40. Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment.
Sionov E; Chang YC; Kwon-Chung KJ
Antimicrob Agents Chemother; 2013 Oct; 57(10):5127-30. PubMed ID: 23836187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
